Compare · GLP-1 agonist
Retatrutide vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Retatrutide | Semaglutide | |
|---|---|---|
| Evidence | 7/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Retatrutide
Retatrutide (Lilly's lab code LY3437943) is an experimental injectable drug being studied for obesity and type 2 diabetes. It has shown some of the biggest weight-loss numbers seen in any trial so far. But as of June 2026 it is not approved anywhere, and the big Phase 3 results that matter most…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.